Alnylam Pharmaceuticals Inc

NASDAQ:ALNY   3:59:53 PM EDT
180.03
-3.77 (-2.05%)
Products

Alnylam Announces New Data From ATTR Amyloidosis Programs At The Peripheral Nerve Society's Meeting

Published: 06/07/2021 11:45 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Announces New Data From Attr Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting.
Alnylam - Study Showed Treatment With Patisiran Achieved Rapid, Sustained Reduction in Serum Ttr Levels in Hattr Amyloidosis Patients With Polyneuropathy Progression.
Alnylam - Additional Results From Pre-specified Patient Subgroups Analysis Included With Encore Presentation of Helios-a Phase 3 Study of Investigational Vutrisiran.